We identified a six-gene signature in RCC cell lines indicative of resistance to CD40-mediated cytotoxicity, offering a potential stratification strategy to predict patient survival and responsiveness to T cell–based immunotherapies. Here, CD40 is linked to renal cell carcinoma.